JENNIFER GOSS: Open Payments
NPI 1548608128 · GRENADA, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$729 in 40 payments from 16 companies in 2025. Trend: 2023 $757 · 2024 $1,058 · 2025 $729
Food & beverage: $729
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $142 |
| ABBVIE INC. | 5 | $90 |
| Lilly USA, LLC | 5 | $86 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $58 |
| Astellas Pharma US Inc | 3 | $53 |
| Novartis Pharmaceuticals Corporation | 2 | $44 |
| Corcept Therapeutics | 2 | $39 |
| Amgen Inc. | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Novo Nordisk Inc | 2 | $33 |
Products named: AIRSUPRA, MOUNJARO, VRAYLAR, Kerendia, Veozah, LEQVIO, Korlym, EVENITY.
Industry payments across MS — which companies pay providers there.
